Press Releases InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results May 13, 2021 Read More » InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results May 6, 2021 Read More » InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021 May 4, 2021 Read More » InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa April 28, 2021 Read More » InMed Pharmaceuticals Announces Voluntary Delisting from TSX April 27, 2021 Read More » InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™ April 26, 2021 Read More » InMed to Participate in Upcoming Investor Conferences in April and May 2022 April 19, 2021 Read More » InMed to Present at Virtual Conferences in March 2021 March 3, 2021 Read More » InMed Announces Closing of US$4.5 Million Private Placement February 16, 2021 Read More » InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results February 11, 2021 Read More » InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results February 6, 2021 Read More » InMed Announces US$4.5 Million Private Placement February 5, 2021 Read More » InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe January 19, 2021 Read More » InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects January 8, 2021 Read More » InMed to Participate at Virtual Conferences in January 2021 January 5, 2021 Read More » InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids December 3, 2020 Read More » InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects November 25, 2020 Read More » InMed Announces Election of Directors November 25, 2020 Read More » InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics November 18, 2020 Read More » InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering November 16, 2020 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021 May 4, 2021 Read More »
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa April 28, 2021 Read More »
InMed to Participate in Upcoming Investor Conferences in April and May 2022 April 19, 2021 Read More »
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results February 11, 2021 Read More »
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results February 6, 2021 Read More »
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe January 19, 2021 Read More »
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects January 8, 2021 Read More »
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids December 3, 2020 Read More »
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects November 25, 2020 Read More »
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics November 18, 2020 Read More »
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering November 16, 2020 Read More »
